Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

1.0K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

645
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
645
Sex-linked Disorders01:43

Sex-linked Disorders

93.0K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
93.0K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K
Amyloid Fibrils03:03

Amyloid Fibrils

10.1K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026
Same author

Stroke in Fabry Disease: Identification of Risk Factors for Stroke in a Large Single-Centre Cohort.

European journal of neurology·2025
Same author

Long-term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey.

European journal of clinical investigation·2025
Same author

Alpha-synuclein inclusions reduced by PIKfyve inhibition in Parkinson disease cell models.

Neurobiology of disease·2025
Same author

Gaucher disease type 3: Classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same author

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy.

Molecular genetics and metabolism reports·2025

Related Experiment Video

Updated: Apr 21, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

7.6K

Fabry disease.

Atison S Thomas, Derralynn A Hughes

    Pediatric Endocrinology Reviews : PER
    |October 28, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Fabry disease (FD) is a genetic disorder where an enzyme deficiency causes substrate buildup, leading to multi-system issues. Enzyme replacement therapy (ERT) helps manage symptoms, but long-term effects and new treatments are under investigation.

    More Related Videos

    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
    06:48

    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

    Published on: March 23, 2022

    2.0K
    Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms
    08:32

    Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms

    Published on: March 22, 2024

    2.0K

    Related Experiment Videos

    Last Updated: Apr 21, 2026

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
    10:16

    In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

    Published on: December 20, 2017

    7.6K
    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
    06:48

    Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

    Published on: March 23, 2022

    2.0K
    Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms
    08:32

    Author Spotlight: Advancing Tendon Research by Developing Mouse Assembloids to Understand Cellular Mechanisms

    Published on: March 22, 2024

    2.0K

    Area of Science:

    • Genetics
    • Metabolic Disorders
    • Enzymology

    Background:

    • Fabry disease (FD) is an X-linked genetic disorder resulting from alpha-galactosidase A deficiency.
    • This deficiency impairs the breakdown of globotriaosylceramide, leading to substrate accumulation in various cell types.
    • The resulting multi-system disorder affects both males and females, presenting with diverse clinical manifestations.

    Purpose of the Study:

    • To review the pathophysiology and clinical features of Fabry disease.
    • To assess the rationale, efficacy, and limitations of current and emerging therapies for FD.
    • To highlight the importance of understanding FD for optimizing patient treatment.

    Main Methods:

    • Literature review of Fabry disease pathophysiology, clinical presentation, and therapeutic interventions.
    • Analysis of the evidence supporting enzyme replacement therapy (ERT) and other treatment modalities.
    • Discussion of ongoing research and future directions in FD treatment.

    Main Results:

    • FD causes neuropathic pain, angiokeratoma, proteinuria, renal failure, cardiac issues, and stroke.
    • Enzyme replacement therapy (ERT) became available in 2001-2003, offering symptomatic improvement.
    • While ERT benefits many symptoms, its long-term impact on the disease's natural history requires further demonstration.

    Conclusions:

    • A thorough understanding of FD pathophysiology and clinical features is crucial for effective therapeutic assessment.
    • Optimizing FD treatment requires evaluating ERT's long-term outcomes, appropriate use of adjunctive therapies, and developing novel strategies like gene therapy.
    • Pharmacologic chaperone therapy and gene therapy represent promising avenues for future Fabry disease management.